Page 9 - Serum Institute Of India

Blurred picture

The sharp cuts in vaccine supply projections are baffling

Taken up Covishield travel issue at highest levels: Adar Poonawalla

Reports suggest India plans to take this matter of non-inclusion of Covishield in the list of approved vaccines for European Union (EU) 'Green Pass' up with the EU

SII manufacturing first batch of Covovax Covid-19 vaccine, says Poonawalla

In March this year, he had said that the clinical trials of Covovax vaccine have begun in India and the company hopes to launch it by September this year.

A jab at veracity

States should not aim to artificially push vaccination numbers

WHO working with AstraZeneca, SII, Indian govt to restart vax shipment

The WHO is urgently trying to work with AstraZeneca, Serum Institute of India (SII) as well as the Indian government to restart shipments of Covid-19 vaccines to countries

AstraZeneca Covid-19 vaccine faces more supply hurdles, now from Thailand

Thailand was slated to receive and administer 6 million AstraZeneca vaccine doses in June but health authorities this week said they would be distributing only 3.5 million of those shots this month

Serum to start clinical trials of Novavax shot for children in July: Report

This week Novavax Inc announced that its vaccine has turned out to be more than 90 per cent effective in clinical trials conducted in the US.

How Biological E could emerge as game changer in India's vaccine race

Company scales up its ambition after government advanced it Rs 1,500 crore for 300 million doses of its vaccine candidate.

Covid-19 vaccine pricing accounts for last-mile delivery, say firms

The cost of logistics is built into the final price of the vaccine, especially when supplying to the private sector

Sustainable pricing

Govt and vaccine makers should be transparent

Covid-19 vaccine Covaxin at Rs 150 not sustainable: Bharat Biotech

Higher price in private market required to offset part of the costs, argues firm

India Coronavirus Dispatch: Lowest daily jump in cases since March 31

New Covid strain on world radar stems from Delta variant, Covaxin is world's third costliest jab and more-news relevant to India's fight against the pandemic

Novavax Covid-19 shot shows 90% efficacy, Serum Institute starts production

On track to make 100 mn doses per month by Q3 of 2021

Novavax's coronavirus vaccine shows 90% efficacy in late stage trial

The US-based firm has partnered with Serum Institute to produce shots locally in India

Setbacks to Serum Institute of India leave world short of Covid shots

The world's largest vaccine maker has been dogged by problems, from a ban on exports to a factory fire, that have hampered its ability to fill orders

Centre fixes maximum price for Covid-19 vaccines at private hospitals

The CoWIN system would also ensure that the prices declared by various private vaccination centres do not exceed the maximum price

Covid-19 vaccination: Govt books 440 million doses with 30% advance

250 mn Covishield and 190 mn Covaxin doses meant for Aug-Dec period

Govt caps maximum price of Covishield, Covaxin, Sputnik V for pvt hospitals

The govt has set the maximum price private hospitals can charge for the three Covid vaccines currently available in the country -- Covishield Rs 780 per dose, Covaxin Rs 1,410, and Sputnik V Rs 1,145

Covid-19 vaccine manufacturers, private hospitals face revenue loss

Back-of-the-envelope calculations show that Serum Institute of India (SII) will lose revenues worth Rs 26.25 crore a month, while Bharat Biotech would lose to the tune of Rs 45 crore a month

Free Covid-19 vaccine for all above 18 years from June 21: PM Modi

Of the total vaccine availability, 75 per cent will be procured by the Centre and the remaining 25 per cent will continue to be available for private hospitals.